GlassScriptPhysician profile
Seth G Friedman
NPI 1053389916
$1,807.93
in general payments reported to CMS, 2019-2025
27 companies · $409 in 2025
The $409 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2021: $148 · 2022: $164 · 2023: $126 · 2024: $102 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $311.76 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $216.81 | 2019-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $208.34 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $151.66 | 2019 | |
| Microvention, INC. | $117.07 | 2021 | |
| Insulet Corporation | $85.14 | 2019-2024 | Omnipod |
| Abbvie INC. | $81.04 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $65.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.53 | 2019-2023 | Synjardy |
| Tandem Diabetes Care, INC. | $58.36 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $51.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.68 | 2019 | |
| Ibsa Pharma INC. | $37.31 | 2019-2023 | Tirosint, Licart |
| Shire North American Group INC | $34.87 | 2019 | |
| Alexion Pharmaceuticals, INC. | $34.25 | 2025 | Strensiq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $33.20 | 2022-2023 | Unithroid |
| Lilly USA, LLC | $27.19 | 2019-2025 | Mounjaro, Zepbound |
| Beta Bionics, INC. | $24.07 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novartis Pharmaceuticals Corporation | $23.46 | 2022 | |
| Zealand Pharma US, INC. | $23.05 | 2022 | |
| Amryt Pharma Holdings LTD | $21.85 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.06 | 2019 | |
| Aytu Biopharma, INC. | $18.64 | 2019 | |
| Cequr Corporation | $17.53 | 2023 | Cequr Simplicity |
| Medtronic Minimed, INC. | $16.80 | 2019 | |
| Pfizer INC. | $14.16 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.